

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**SCHEDULE 14A**  
Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934

---

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only** (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under §240.14a-12

**BridgeBio Pharma, Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
  - Fee paid previously with preliminary materials.
  - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
- 
- 
-



BRIDGEBIO PHARMA, INC.  
3160 PORTER DRIVE  
SUITE 250  
PALO ALTO, CA 94304

# Your **Vote** Counts!

**BRIDGEBIO PHARMA, INC.**

2024 Annual Meeting  
Vote by June 20, 2024  
11:59 PM ET



V48683-P07810

## You invested in BRIDGEBIO PHARMA, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 21, 2024.**

### Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 7, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit [www.ProxyVote.com](http://www.ProxyVote.com), (2) call 1-800-579-1639 or (3) send an email to [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com). If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit [www.ProxyVote.com](http://www.ProxyVote.com)

Control #

#### Smartphone users

Point your camera here and vote without entering a control number



#### Vote Virtually at the Meeting\*

June 21, 2024  
9:00 a.m. Pacific Time

Virtually at:  
[www.virtualshareholdermeeting.com/BBIO2024](http://www.virtualshareholdermeeting.com/BBIO2024)

\*Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommendations						
<p>1. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal.</p> <p><b>Nominees:</b></p> <table border="0"> <tr> <td>01) Eric Aguiar, M.D.</td> <td>04) Fred Hassan</td> </tr> <tr> <td>02) Jennifer E. Cook</td> <td>05) Ali J. Satvat</td> </tr> <tr> <td>03) Andrea J. Ellis</td> <td></td> </tr> </table>	01) Eric Aguiar, M.D.	04) Fred Hassan	02) Jennifer E. Cook	05) Ali J. Satvat	03) Andrea J. Ellis		<p>✔ For</p>
01) Eric Aguiar, M.D.	04) Fred Hassan						
02) Jennifer E. Cook	05) Ali J. Satvat						
03) Andrea J. Ellis							
<p>2. To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.</p>	<p>✔ For</p>						
<p>3. To ratify the appointment of Deloitte &amp; Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.</p>	<p>✔ For</p>						
<p>4. To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.</p>	<p>✔ For</p>						
<p><b>NOTE:</b> To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.</p>							

Prefer to receive an email instead? While voting on [www.ProxyVote.com](http://www.ProxyVote.com), be sure to click "Delivery Settings".